health π©Ί Novartis moves forward with IL-6 inhibitor study
Novartis is starting a Phase 3 trial for its anti-IL-6 antibody. This study aims to prevent cardiovascular events in specific patient groups. The trial launch is happening at the ESC Congress in Munich. This move comes despite a recent failure experienced by Novo in related research. The results of this trial will be closely watched by the medical community. π©Ί